Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

Conditions

• Maturity Onset Diabetes of the Young

Eligibility Criteria

Sex

ALL

Age

10 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Liraglutide — DRUG
  Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.

Study Details

The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.

Key Dates

Start date

May 8, 2025

Status verified

Dec 2024

Primary completion

Aug 31, 2026

Completion

Jan 31, 2027

Study Design

Enrollment

50 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: liraglutide treatment
  After baseline evaluation of enteroendocrine levels and metabolism, study participants will be prescribed liraglutide. Titration of liraglutide will be as follows: 1) Starting dose of liraglutide 0.6 mg daily for 1 week, 2) Increase to liraglutide 1.2 mg daily for 1 week, and 3) Maintain at final dose of liraglutide 1.8 mg daily. If study participants are unable to tolerate liragultide 1.8 mg daily due to side effects for 1 week, then will decrease back to liraglutide 1.2 mg daily.

Primary Outcome Measure

Blood sugar control - HbA1C [ Time Frame: Baseline and 3 months after study treatment initiation ]

Central Contacts

• Mansa Krishnamurthy, M.D.
  513-636-4744
  [email protected]

Locations (1)

Find similar trials in Cincinnati, OH